Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Core One Labs Inc. (OTCQB:CLABF) has marked a significant milestone with the successful synthetic production of psilocin at its GMP facility, achieved by its subsidiary Awakened Biosciences Inc.. This development showcases operational synergies from a recent acquisition, enhancing the company's strategic goal of becoming a large-scale supplier of psychedelic compounds. CEO Joel Shacker emphasized that this achievement is foundational for future production and research of psilocybin and other psychedelic compounds. The production was led by Dr. Tony Durst, a specialist in medicinal chemistry, who aims to advance innovations in psychedelics research. Awakened currently holds three provisional patents for psilocybin production methods, further solidifying Core One's position in the emerging psychedelics market.